Tracking and Exploring the Source of Viral REbound

Study Overview
=================
Brief Summary
-----------------
Phylogenic analysis of viruses hosted in marker positive reservoir cells including CD32a+ CD4 T lymphocytes and rebounding viruses after treatment interruption

Official Title
-----------------
Tracking and Exploring the Source of Viral REbound

Conditions
-----------------
Hiv

Intervention / Treatment
-----------------
* Other: no drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Age>18year old Nadir CD4>200/mm3 CD4/CD8 ratio> 0.5 Continuous antiretroviral therapy for more than 2 years Plasma Human Immunodeficiency Virus (HIV) 1 Ribonucleic acid (RNA) <50 copies/ml in the last 2 years Viral Load (VL)<20copies at inclusion Patients who are willing to participate and who understand the trial (particularly, the obligation to have protected intercourse during the study). Informed consent Short half-life treatment Health insurance A subset of CD4 (T4cells) express CD32a. Exclusion Criteria: - Acquired Immune Deficiency Syndom (AIDS) Pregnancy Human immunodeficiency virus (HIV)-2 co infection Thrombopenia Neurological events during primary infection Hepatitis B + (HBV+) Hepatitis C + (HCV+) Cancer during the last 5 years. Life expectancy < 12 months Autoimmunity Acute infectious disease in the last 60 days. Hemoglobin<7g/dl Glomerular filtration < 60ml/min Refusing protected intercourse Risk of HIV transmission Psychiatric disorders. Alcool and drug abuse Involvement in another clinical trial evaluating a therapeutic. Being under tutorship Being deprived of liberty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Antiretroviral therapy<br>Stopping antiretroviral therapy | Other: no drug<br>* Stopping antiretroviral therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 1 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 2 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 3 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 4 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 5 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 6 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 8 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 10 | 
| Genetic Cartography | Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml | Week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV reservoirs, HIV persistence, Viral rebound